Pasar al contenido principal

BLOQUEAR LA ENTRADA DE VIRUS CON ENVUELTA EN CELULAS INMUNES: NUEVOS ANTICUERPOS MONOCLONALES E INTERRUPCION DE LA CASCADA INTRACELULAR

PID2019-109870RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Understanding the neurological implications of acute and long COVID using brain organoids

  • García-González, Laura
  • Martí-Sarrias, Andrea
  • Puertas, Maria C.
  • Bayón-Gil, Ángel
  • Resa Infante, Patricia
  • Martinez Picado, Javier
  • Navarro, Arcadi
  • Acosta, Sandra
As early as in the acute phase of the coronavirus disease 2019 (COVID-19) pandemic, the research community voiced concerns about the long-term implications of infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), like many other viruses, can trigger chronic disorders that last months or even years. Long COVID, the chronic and persistent disorder lasting more than 12 weeks after the primary infection with SARS-CoV-2, involves a variable number of neurological manifestations, ranging from mild to severe and even fatal. In vitro and in vivo modeling suggest that SARS-CoV-2 infection drives changes within neurons, glia and the brain vasculature. In this Review, we summarize the current understanding of the neuropathology of acute and long COVID, with particular emphasis on the knowledge derived from brain organoid models. We highlight the advantages and main limitations of brain organoids, leveraging their human-derived origin, their similarity in cellular and tissue architecture to human tissues, and their potential to decipher the pathophysiology of long COVID., This work is funded by Fundació la Marató de TV3 (2021-30/31/32) to S.A., J.M.-P. and A.N., and project 3D4COVID by Merck Sharp and Dohme Investigator Studies Program (code MISP# IIS 60258) to J.M.-P. and S.A. J.M.-P. is supported by grant PID2019-109870RB-I00 from Ministerio de Ciencia e Innovación. L.G.-G. is supported by a Margarita Salas Fellowship (2021UPF-MS-28) from Ministerio de Ciencia e Innovación, funded by the European Union-NextGenerationEU, Ministry of Universities and Recovery, Transformation and Resilience Plan, through Universitat Pompeu Fabra.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses

  • Perez-Zsolt, Daniel
  • Muñoz-Basagoiti, Jordana
  • Rodón, Jordi
  • Elousa, Marc
  • Raïch-Regué, Dàlia
  • Risco, Cristina
  • Sachse, Martín
  • Pino, María
  • Gumber, Sanjeev
  • Paiardini, Mirko
  • Chojnacki, Jakub
  • Erkizia, tziar
  • Muñiz-Trabudua, Xabier
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Noguera, Marc
  • Paredes, Roger
  • Trinité, Benjamin
  • Tarrés-Freixas, Ferrán
  • Blanco, Ignacio
  • Guallar, Victor
  • Carrillo, Jorge
  • Blanco, Julià
  • Telenti, Amalio
  • Heyn, Holger
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Martínez-Picado, Javier
  • Vergara-Alert, Júlia
  • Izquierdo-Useros, Núria
COVID-19 pandemic is not yet under control by vaccination, and effective antivirals are critical for preparedness. Here we report that macrophages and dendritic cells, key antigen presenting myeloid cells (APCs), are largely resistant to SARS-CoV-2 infection. APCs effectively captured viruses within cellular compartments that lead to antigen degradation. Macrophages sense SARS-CoV-2 and released higher levels of cytokines, including those related to cytokine storm in severe COVID-19. The sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169) present on APCs, which interacts with sialylated gangliosides on membranes of retroviruses or filoviruses, also binds SARS-CoV-2 via GM1. Blockage of Siglec-1 receptors by monoclonal antibodies reduces SARS-CoV-2 uptake and transfer to susceptible target cells. APCs expressing Siglec-1 and carrying SARS-CoV-2 are found in pulmonary tissues of non-human primates. Single cell analysis reveals the in vivo induction of cytokines in those macrophages. Targeting Siglec-1 could offer cross-protection against SARS-CoV-2 and other enveloped viruses that exploit APCs for viral dissemination, including those yet to come in future outbreaks., The research of CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols pharmaceutical. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). J.M-P. is supported by grant PID2019-109870RB-I00 from the Spanish Ministry of Science and Innovation and in part also by Grifols. CR lab is funded by RTI2018-094445-B100 (MCIU/AEI/FEDER, UE). The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). The NHP study was primarily supported by YNPRC Coronavirus Pilot Research Project Program grant to M.Pa. under award P51 OD11132, Emergent Venture Fast grant program to MPa under awards #2206 and #2144, and William and Lula Pitts Foundation (to MPa)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells

  • Perez-Zsolt, Daniel
  • Muñoz-Basagoiti, Jordana
  • Rodón, Jordi
  • Elosua-Bayes, Marc
  • Raïch-Regué, Dàlia
  • Risco, Cristina
  • Sachse, Martín
  • Pino, María
  • Gumber, Sanjeev
  • Paiardini, Mirko
  • Chojnacki, Jakub
  • Erkizia, tziar
  • Muñiz-Trabudua, Xabier
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Noguera, Marc
  • Paredes, Roger
  • Trinité, Benjamin
  • Tarrés-Freixas, Ferrán
  • Blanco, Ignacio
  • Guallar, Victor
  • Carrillo, Jorge
  • Blanco, Julià
  • Telenti, Amalio
  • Heyn, Holger
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Martínez-Picado, Javier
  • Vergara-Alert, Júlia
  • Izquierdo-Useros, Núria
Antigen-presenting cells (APCs) may be resistant to SARS-CoV-2 infection but still contribute to viral pathogenesis. Lectins such as sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169) mediate the attachment of viruses to APCs. Here, we show that APCs effectively capture SARS-CoV-2 within compartments via recognition of Siglec-1. This receptor interacts with sialylated gangliosides on membranes of SARS-CoV-2 variants, as previously shown for retroviruses or filoviruses [1]. Blockage of Siglec-1 on monocyte-derived dendritic cells (MDDCs) decreased SARS-CoV-2 viral transfer or trans-infection to bystander target cells. However, monocyte-derived macrophages (MDMs) capturing SARS-CoV-2 via Siglec-1 did not transmit infectious particles. The presence of pulmonary APCs co-expressing Siglec-1 and SARS-CoV-2 corroborated these findings in vivo., The research of the CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols Pharmaceutical. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). N.I.-U. is supported by the grant PID2020-117145RB-I00 from the Spanish Ministry of Science and Innovation. J.M.-P. is supported by the grant PID2019-109870RB-I00 from the Spanish Ministry of Science and Innovation and in part also by Grifols. The C.R. laboratory is funded by RTI2018-094445-B100 (MCIU/AEI/FEDER, UE). The NHP study was primarily supported by a YNPRC Coronavirus Pilot Research Project Program grant to M.Pa. under award P51 OD11132, Emergent Venture Fast grant program to M.Pa. under awards #2206 and #2144, and William and Lula Pitts Foundation (to M.Pa.). X.M.-T. is supported by the Spanish Ministry of Science and Innovation and the European Regional Development Fund under agreement BES-2017-082900., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Understanding the neurological implications of acute and long COVID using brain organoids

  • García-González, Laura
  • Martí-Sarrias, Andrea
  • Puertas, Maria C.
  • Bayón-Gil, Ángel
  • Resa-Infante, Patricia
  • Martinez-Picado, Javier
  • Navarro, Arcadi
  • Acosta, Sandra
  • Acosta, Sandra
© 2023. Published by The Company of Biologists Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed., As early as in the acute phase of the coronavirus disease 2019 (COVID-19) pandemic, the research community voiced concerns about the long-term implications of infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), like many other viruses, can trigger chronic disorders that last months or even years. Long COVID, the chronic and persistent disorder lasting more than 12 weeks after the primary infection with SARS-CoV-2, involves a variable number of neurological manifestations, ranging from mild to severe and even fatal. In vitro and in vivo modeling suggest that SARS-CoV-2 infection drives changes within neurons, glia and the brain vasculature. In this Review, we summarize the current understanding of the neuropathology of acute and long COVID, with particular emphasis on the knowledge derived from brain organoid models. We highlight the advantages and main limitations of brain organoids, leveraging their human-derived origin, their similarity in cellular and tissue architecture to human tissues, and their potential to decipher the pathophysiology of long COVID., This work is funded by Fundació la Marató de TV3 (2021-30/31/32) to S.A., J.M.-P. and A.N., and project 3D4COVID by Merck Sharp and Dohme Investigator Studies Program (code MISP# IIS 60258) to J.M.-P. and S.A. J.M.-P. is supported by grant PID2019-109870RB-I00 from Ministerio de Ciencia e Innovación. L.G.-G. is supported by a Margarita Salas Fellowship (2021UPF-MS-28) from Ministerio de Ciencia e Innovación, funded by the European Union-NextGenerationEU, Ministry of Universities and Recovery, Transformation and Resilience Plan, through Universitat Pompeu Fabra., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Understanding the neurological implications of acute and long COVID using brain organoids

  • García-González, Laura
  • Martí-Sarrias, Andrea
  • Puertas, Maria C.
  • Bayón-Gil, Ángel
  • Resa Infante, Patricia
  • Martinez Picado, Javier
  • Navarro, Arcadi
  • Acosta, Sandra
As early as in the acute phase of the coronavirus disease 2019 (COVID-19) pandemic, the research community voiced concerns about the long-term implications of infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), like many other viruses, can trigger chronic disorders that last months or even years. Long COVID, the chronic and persistent disorder lasting more than 12 weeks after the primary infection with SARS-CoV-2, involves a variable number of neurological manifestations, ranging from mild to severe and even fatal. In vitro and in vivo modeling suggest that SARS-CoV-2 infection drives changes within neurons, glia and the brain vasculature. In this Review, we summarize the current understanding of the neuropathology of acute and long COVID, with particular emphasis on the knowledge derived from brain organoid models. We highlight the advantages and main limitations of brain organoids, leveraging their human-derived origin, their similarity in cellular and tissue architecture to human tissues, and their potential to decipher the pathophysiology of long COVID., This work is funded by Fundació la Marató de TV3 (2021-30/31/32) to S.A., J.M.-P. and A.N., and project 3D4COVID by Merck Sharp and Dohme Investigator Studies Program (code MISP# IIS 60258) to J.M.-P. and S.A. J.M.-P. is supported by grant PID2019-109870RB-I00 from Ministerio de Ciencia e Innovación. L.G.-G. is supported by a Margarita Salas Fellowship (2021UPF-MS-28) from Ministerio de Ciencia e Innovación, funded by the European Union-NextGenerationEU, Ministry of Universities and Recovery, Transformation and Resilience Plan, through Universitat Pompeu Fabra.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles

  • Benet, Susana|||0000-0002-2219-8826
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Drobniewski, Francis
  • Kontsevaya, Irina
  • Arias, Lilibeth|||0000-0002-2469-8832
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Urrea, Víctor|||0000-0002-2577-856X
  • Ong, Ruo-Yan
  • Luquin Fernandez, Marina de la Milagrosa|||0000-0002-6015-3282
  • Dupont, Maeva|||0000-0002-0514-4447
  • Chojnacki, Jakub|||0000-0002-4457-8096
  • Dalmau, Judith|||0000-0001-7513-3711
  • Cardona, Paula|||0000-0002-8613-9390
  • Neyrolles, Olivier|||0000-0003-0047-5885
  • Lugo-Villarino, Geanncarlo|||0000-0003-4620-8491
  • Vérollet, Christel|||0000-0002-1079-9085
  • Julián, Esther|||0000-0002-6558-3978
  • Furrer, Hansjakob
  • Günthard, Huldrych F.
  • Crocker, Paul R.
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Fellay, Jacques|||0000-0002-8240-939X
  • McLaren, Paul J.
  • Telenti, Amalio
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
The identification of individuals with null alleles enables studying how the loss of gene function affects infection. We previously described a non-functional variant in SIGLEC1, which encodes the myeloid-cell receptor Siglec-1/CD169 implicated in HIV-1 cell-to-cell transmission. Here we report a significant association between the SIGLEC1 null variant and extrapulmonary dissemination of Mycobacterium tuberculosis (Mtb) in two clinical cohorts comprising 6,256 individuals. Local spread of bacteria within the lung is apparent in Mtb-infected Siglec-1 knockout mice which, despite having similar bacterial load, developed more extensive lesions compared to wild type mice. We find that Siglec-1 is necessary to induce antigen presentation through extracellular vesicle uptake. We postulate that lack of Siglec-1 delays the onset of protective immunity against Mtb by limiting antigen exchange via extracellular vesicles, allowing for an early local spread of mycobacteria that increases the risk for extrapulmonary dissemination.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation

  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Felip, Eudald|||0000-0002-3812-1313
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Gohr, André
  • Ruiz Riol, Marta|||0000-0003-1899-8879
  • Massanella, Marta|||0000-0002-3326-151X
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Badia, Roger|||0000-0003-3982-7577
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Ballana, Ester|||0000-0002-5215-7363
The persistence of latent HIV reservoirs allows for viral rebound upon antiretroviral therapy interruption, hindering effective HIV-1 cure. Emerging evidence suggests that modulation of innate immune stimulation could impact viral latency and contribute to the clearing of HIV reservoir. Here, the latency reactivation capacity of a subclass of selective JAK2 inhibitors was characterized as a potential novel therapeutic strategy for HIV-1 cure. Notably, JAK2 inhibitors reversed HIV-1 latency in non-clonal lymphoid and myeloid in vitro models of HIV-1 latency and also ex vivo in CD4+ T cells from ART+ PWH, albeit its function was not dependent on JAK2 expression. Immunophenotypic characterization and whole transcriptomic profiling supported reactivation data, showing common gene expression signatures between latency reactivating agents (LRA; JAK2i fedratinib and PMA) in contrast to other JAK inhibitors, but with significantly fewer affected gene sets in the pathway analysis. In depth evaluation of differentially expressed genes, identified a significant upregulation of IRF7 expression despite the blockade of the JAK-STAT pathway and downregulation of proinflammatory cytokines and chemokines. Moreover, IRF7 expression levels positively correlated with HIV latency reactivation capacity of JAK2 inhibitors and also other common LRAs. Collectively, these results represent a promising step towards HIV eradication by demonstrating the potential of innate immune modulation for reducing the viral reservoir through a novel pathway driven by IRF7.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA (LoViReTs)

  • Gálvez, Cristina|||0000-0002-2286-6193
  • Urrea, Víctor|||0000-0002-2577-856X
  • García Guerrero, María del Carmen|||0000-0001-7651-7629
  • Bernal, Sílvia
  • Benet, Susana|||0000-0002-2219-8826
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Bailón, Lucía|||0000-0001-7277-9314
  • Dalmau, Judith|||0000-0001-7513-3711
  • Martinez, Andrea
  • Nieto Gil-Ortega, Aroa|||0000-0001-8477-5062
  • Leal, Lorna|||0000-0001-7887-6027
  • García, Felipe|||0000-0001-7658-5832
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Salgado, Maria|||0000-0003-1551-7216
HIV cure strategies aim to eliminate viral reservoirs that persist despite successful antiretroviral therapy (ART). We have previously described that 9% of HIV-infected individuals who receive ART harbor low levels of provirus (LoViReTs). We selected 22 LoViReTs matched with 22 controls ART suppressed for more than 3 years with fewer than 100 and more than 100 HIV-DNA copies/10 6 CD4 + T cells, respectively. We measured HIV reservoirs in blood and host genetic factors. Fourteen LoViReTs underwent leukapheresis to analyze replication-competent virus, and HIV-DNA in CD4 + T-cell subpopulations. Additionally, we measured HIV-DNA in rectum and/or lymph node biopsies from nine of them. We found that LoViReTs harbored not only lower levels of total HIV-DNA, but also significantly lower intact HIV-DNA, cell-associated HIV-RNA, and ultrasensitive viral load than controls. The proportion of intact versus total proviruses was similar in both groups. We found no differences in the percentage of host factors. In peripheral blood, 71% of LoViReTs had undetectable replication-competent virus. Minimum levels of total HIV-DNA were found in rectal and lymph node biopsies compared with HIV-infected individuals receiving ART. The main contributors to the reservoir were short-lived transitional memory and effector memory T cells (47% and 29%, respectively), indicating an altered distribution of the HIV reservoir in the peripheral T-cell subpopulations of LoViReTs. In conclusion, LoViReTs are characterized by low levels of viral reservoir in peripheral blood and secondary lymphoid tissues, which might be explained by an altered distribution of the proviral HIV-DNA towards more short-lived memory T cells. LoViReTs can be considered exceptional candidates for future interventions aimed at curing HIV.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Opportunities for CAR-T Cell Immunotherapy in HIV Cure

  • Campos-Gonzalez, Gerard|||0000-0002-5442-4963
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Salgado, Maria|||0000-0003-1551-7216
Chimeric antigen receptor (CAR) technology is having a huge impact in the blood malignancy field and is becoming a well-established therapy for many types of leukaemia. In recent decades, efforts have been made to demonstrate that CAR-T cells have potential as a therapy to achieve a sterilizing cure for human immunodeficiency virus (HIV) infection. However, translation of this technology to the HIV scenario has not been easy, as many challenges have appeared along the way that hinder the consolidation of CAR-T cells as a putative therapy. Here, we review the origin and development of CAR-T cells, describe the advantages of CAR-T cell therapy in comparison with other therapies, and describe the major obstacles currently faced regarding application of this technology in the HIV field, specifically, viral escape, CAR-T cell infectivity, and accessibility to hidden reservoirs. Nonetheless, promising results in successfully tackling some of these issues that have been obtained in clinical trials suggest a bright future for CAR-T cells as a consolidated therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Post COVID-19 Condition in Children and Adolescents, An Emerging Problem

  • Izquierdo-Pujol, Jon|||0000-0002-5903-9909
  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Dalmau, Judith|||0000-0001-7513-3711
  • Gonzalez-Aumatell, Alba|||0000-0001-9594-4300
  • Carreras-Abad, Clara|||0000-0002-9068-3233
  • Méndez Hernández, Maria|||0000-0001-5697-2763
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection became a pandemic in 2020 and by March 2022 had caused more than 479 million infections and 6 million deaths worldwide. Several acute and long-term symptoms have been reported in infected adults, but it remains unclear whether children/adolescents also experience persistent sequelae. Hence, we conducted a review of symptoms and pathophysiology associated with post-coronavirus disease 2019 (post-COVID-19) condition in children and adolescents. We reviewed the scientific literature for reports on persistent COVID-19 symptoms after SARS-CoV-2 infection in both children/adolescents and adults from 1 January 2020 to 31 March 2022 (based on their originality and relevance to the broad scope of this review, 26 reports were included, 8 focused on adults and 18 on children/adolescents). Persistent sequelae of COVID-19 are less common in children/adolescents than in adults, possibly owing to a lower frequency of SARS-CoV-2 infection and to the lower impact of the infection itself in this age group. However, cumulative evidence has shown prolonged COVID-19 to be a clinical entity, with few pathophysiological associations at present. The most common post-COVID-19 symptoms in children/adolescents are fatigue, lack of concentration, and muscle pain. In addition, we found evidence of pathophysiology associated with fatigue and/or headache, persistent loss of smell and cough, and neurological and/or cardiovascular symptoms. This review highlights the importance of unraveling why SARS-CoV-2 infection may cause post-COVID-19 condition and how persistent symptoms might affect the physical, social, and psychological well-being of young people in the future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy

  • Resa-Infante, Patricia|||0000-0002-1727-592X
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Muñiz-Trabudua, Xabier|||0000-0002-1142-4381
  • Linty, Federica
  • Bentlage, Arthur E.H.
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Rispens, Theo
  • Vidarsson, Gestur
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
New therapies to treat or prevent viral infections are essential, as recently observed during the COVID-19 pandemic. Here, we propose a therapeutic strategy based on monoclonal antibodies that block the specific interaction between the host receptor Siglec-1/CD169 and gangliosides embedded in the viral envelope. Antibodies are an excellent option for treating infectious diseases based on their high specificity, strong targeting affinity, and relatively low toxicity. Through a process of humanization, we optimized monoclonal antibodies to eliminate sequence liabilities and performed biophysical characterization. We demonstrated that they maintain their ability to block viral entry into myeloid cells. These molecular improvements during the discovery stage are key if we are to maximize efforts to develop new therapeutic strategies. Humanized monoclonal antibodies targeting CD169 provide new opportunities in the treatment of infections caused by ganglioside-containing enveloped viruses, which pose a constant threat to human health. In contrast with current neutralizing antibodies that bind antigens on the infectious particle, our antibodies can prevent several types of enveloped viruses interacting with host cells because they target the host CD169 protein, thus becoming a potential pan-antiviral therapy.